February 12, 2019 Stephen Tulipano Stoneham, MA 02180Non-Competition Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Delaware
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Chief Financial Officer, effective as of March 18, 2019 (the “Employment Date”).
Edward Kaye, M.D. [ADDRESS]Confidentiality and Non-Competition Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Delaware
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Chief Executive Officer, effective as of October 17, 2017 (the “Employment Date”).
September 8, 2017 Barry Ticho, M.D., Ph.D. Newton, MAEmployment Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
On behalf of Stoke Therapeutics, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Company’s Chief Medical Officer, effective as of October 2, 2017 (the “Employment Date”).
CONSULTING AGREEMENTConsulting Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations
This Agreement is made as of October 24, 2014 between ASOthera Pharmaceuticals, Inc. (the “Company”) and Adrian Krainer, PhD (the “Consultant”), an employee of the Cold Spring Harbor Laboratory (“CSHL”). The Company is engaged in scientific research relating to the development of antisense-based drugs, therapies, diagnostic and research tools, products, services and intellectual property (the “Field”). The Consultant has experience in the Field, and the Company seeks to benefit from the Consultant’s expertise by retaining the Consultant as a consultant. The Consultant wishes to perform consulting services in the Field for the Company. Accordingly, the Company and the Consultant agree as follows:
November 20, 2015 Huw M. Nash, Ph.D. Lexington, MA 02421Confidentiality Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • New York
On behalf of ASOthera Pharmaceuticals, Inc. (the “Company”), this letter agreement (the “Agreement”) sets forth the terms and conditions of your appointment as the Chief Executive Officer of the Company, effective as of October 24, 2014 (the “Employment Date”).
LICENSE AGREEMENT BETWEEN UNIVERSITY OF SOUTHAMPTON AND ASOTHERA PHARMACEUTICALS, INC.License Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • England and Wales
This License Agreement (“Agreement”) is made effective as of the date of last signature as written below (the “Effective Date”) by and between University of Southampton, whose administrative offices are at University Road, Highfield, Southampton, SO17 1BJ (“University”) and ASOthera Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“ASOthera”), having an office at 3 Preston Court, Suite 102, Bedford, MA 01730.
LICENSE AGREEMENT BETWEEN COLD SPRING HARBOR LABORATORY AND ASOTHERA PHARMACEUTICALS, INC.Restricted Stock Purchase Agreement • May 23rd, 2019 • Stoke Therapeutics, Inc. • Pharmaceutical preparations • New York
This License Agreement (“Agreement”) is made effective as of July 31, 2015 (the “Effective Date”) by and between Cold Spring Harbor Laboratory, a nonprofit New York State education corporation (“CSHL”) having an office at One Bungtown Road, Cold Spring Harbor, New York 11724 and ASOthera Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware (“ASOthera”), having an office at One Bungtown Road, Cold Spring Harbor, New York 11724.
